Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyMosunetuzumab, the First Bispecific Approved for Follicular Lymphoma

Could this usher in a new era in follicular lymphoma treatment?

The recent approval of mosunetuzumab (Lunsumio, Genentech), a bispecific antibody, marks a significant advancement in the treatment of follicular lymphoma. This innovative therapy, which targets both CD20 and CD3 proteins, offers a potent alternative to conventional treatments, harnessing the body’s immune response to eliminate lymphoma cells.

Key Points

  • Mosunetuzumab is a bispecific antibody-based T-cell engager with two binding sites.
  • It targets CD20, a protein found on most lymphoma cells, and CD3 protein, present on immune T cells.
  • Mosunetuzumab redirects immune T cells to recognize lymphoma cells, activating them to initiate the process of killing the lymphoma cells.
  • It functions as both a targeted therapy and immunotherapy, without involving chemotherapy.
  • Mosunetuzumab has a distinct design aimed at redirecting endogenous immune T cells to target and treat lymphoma cells.
  • It is readily available and does not require personalized manufacturing for each patient.
  • Mosunetuzumab demonstrates the capacity of activated immune cells to eliminate lymphoma cells, erasing the need for chemotherapy and achieving deep and curable remissions.

According to the American Cancer Society, about 20% of lymphomas in the United States are follicular lymphomas.

More on Follicular Lymphoma

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form